Giảm nguy cơ tim mạch với semaglutide dùng một lần mỗi tuần ở những đối tượng mắc bệnh tiểu đường loại 2: phân tích hậu nghiệm về giới tính, tuổi tác và hồ sơ nguy cơ tim mạch ban đầu trong nghiên cứu SUSTAIN 6

Springer Science and Business Media LLC - Tập 18 Số 1 - 2019
Lawrence A. Leiter1, Stephen C. Bain2, Irene Hramiak3, Esteban Jódar4, Sten Madsbad5, Theis Gondolf6, Thomas K. Hansen6, Ingrid Holst6, Ildiko Lingvay7
1Division of Endocrinology and Metabolism, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, University of Toronto, 61 Queen St. East #6121, Toronto, ON, M5C 2T2, Canada
2Diabetes Research Unit Cymru, Swansea University Medical School, Swansea, Wales, UK
3University of Western Ontario, London, ON, Canada
4Hospital Universitario Quirónsalud, Madrid, Spain
5University of Copenhagen, Hvidovre, Denmark
6Novo Nordisk A/S, Søborg, Denmark
7UT Southwestern Medical Center, Dallas, TX, USA

Tóm tắt

Tóm tắt Đặt vấn đề Nghiên cứu SUSTAIN 6 đã chứng minh rằng semaglutide dùng một lần mỗi tuần (0.5 và 1.0 mg) đã giảm đáng kể các sự kiện tim mạch bất lợi lớn (MACE) so với giả dược ở những người mắc bệnh tiểu đường loại 2 (T2D) và có nguy cơ tim mạch cao. Các tác động của giới tính, độ tuổi và nguy cơ tim mạch ban đầu lên kết quả là những yếu tố quan trọng cần xem xét cho các nghiên cứu tiếp theo. Phương pháp Các chủ thể được phân nhóm theo giới tính, độ tuổi (50–65 tuổi và > 65 tuổi), và hồ sơ nguy cơ tim mạch ban đầu (có tiền sử nhồi máu cơ tim [MI] hoặc đột quỵ so với không có tiền sử MI hoặc đột quỵ, và bệnh tim mạch đã được xác định [CVD] so với chỉ có các yếu tố nguy cơ tim mạch, bao gồm các đối tượng có bệnh thận mãn tính). Thời gian đến MACE và các thành phần riêng lẻ của nó (tử vong do tim mạch, nhồi máu cơ tim không tử vong, đột quỵ không tử vong), nhập viện do đau thắt ngực không ổn định hoặc suy tim, và tái vascular hóa (mạch vành và ngoại biên) đã được phân tích cho tất cả các nhóm con. Các phân tích bổ sung đã được thực hiện cho giới và độ tuổi để điều tra sự thay đổi từ ban đầu ở HbA1c và trọng lượng cơ thể, cũng như độ dung nạp của thuốc.

Từ khóa

#semaglutide #bệnh tiểu đường loại 2 #nguy cơ tim mạch #MACE #giới tính #tuổi tác #nghiên cứu SUSTAIN 6

Tài liệu tham khảo

American Diabetes Association. Standards of medical care in diabetes 2018. Diabetes Care. 2018;41(Suppl 1):S1–135.

American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes 2019. Diabetes Care. 2019;42(Suppl 1):S103–23.

Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.

Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2018(41):2669–701.

Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58:7370–80.

Ozempic marketing authorisation 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic. Accessed 7 May 2019.

Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251–60.

Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341–54.

Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258–66.

Aroda VR, Bain SC, Cariou B, Piletić M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355–66.

Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103:2291–301.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.

Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275–86.

Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo controlled trial. Lancet Diab Endocrinol. 2019;7:356–67.

International Conference on Harmonisation-World Health Organization Guideline for Good Clinical Practice. ICH harmonised tripartite guideline good clinical practice 2016. https://www.ich.org/products/guidelines/efficacy/efficacy-single/article/integrated-addendum-good-clinical-practice.html. Accessed 22 Mar 2019.

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.

Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–95.

Shehadeh N, Raz I, Nakhleh A. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. Cardiovasc Diabetol. 2018;17:117.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39.

Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–29.

Eli Lilly Press release, 2018. Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes. https://investor.lilly.com/node/39796/pdf. Accessed May 2018.

Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, et al. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol. 2017;16:31.

Li Y, Rosenblit PD. Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect? Curr Cardiol Rep. 2018;20:113.

Witkowski M, Wilkinson L, Webb N, Weids A, Glah D, Vrazic H. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1–2 oral anti-diabetic drugs. Diabetes Ther. 2018;9:1149–67.

Aroda V, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1–7 trials. Diabetes Metab. 2019. https://doi.org/10.1016/j.diabet.2018.12.001 (Epub ahead of print).

Mishriky BM, Cummings DM, Powell JR, Sewell KA, Tanenberg RJ. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2019;45:102–9.

Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, et al. Effect of once-weekly exenatide on clinical outcomes according to baseline risk in patients with type 2 diabetes mellitus: insights from the EXSCEL trial. J Am Heart Assoc. 2018;7:e009304.

Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57:1542–51.

Gouni-Berthold I, Berthold HK, Mantzoros CS, Böhm M, Krone W. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care. 2008;31:1389–91.

Kautzky-Willer A, Kamyar MR, Gerhat D, Handisurya A, Stemer G, Hudson S, et al. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. Gend Med. 2010;7:571–83.

Sekerija M, Poljicanin T, Erjavec K, Liberati-Cizmek AM, Prasek M, Metelko Z. Gender differences in the control of cardiovascular risk factors in patients with type 2 diabetes—a cross-sectional study. Intern Med. 2012;51:161–6.

Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, et al. Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial. Ann Intern Med. 2018. https://doi.org/10.7326/m18-1569.

National Diabetes Statistics Report. 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed 7 May 2019.

Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350–7.

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, et al. Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation. 2018;138:2884–94.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20:42–9.

NCT03811561. https://clinicaltrials.gov/ct2/show/NCT03811561. Accessed 7 May 2019.

NCT03819153. https://clinicaltrials.gov/ct2/show/NCT03819153. Accessed 7 May 2019.

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–94.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 18 Số 1

Thông tin tác giả